

Corrado Barbui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7695262/publications.pdf>

Version: 2024-02-01

431
papers

20,319
citations

20797

60
h-index

15249

126
g-index

458
all docs

458
docs citations

458
times ranked

19865
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. <i>Lancet, The</i> , 2013, 382, 951-962.	6.3	2,094
2	Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. <i>Lancet, The</i> , 2009, 373, 746-758.	6.3	1,459
3	Imputing missing standard deviations in meta-analyses can provide accurate results. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 7-10.	2.4	1,219
4	Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. <i>Journal of Hepatology</i> , 2016, 65, 589-600.	1.8	965
5	Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2018, 5, 727-738.	3.7	722
6	Mental health and psychosocial support in humanitarian settings: linking practice and research. <i>Lancet, The</i> , 2011, 378, 1581-1591.	6.3	462
7	Efficacy of Psychotherapies for Borderline Personality Disorder. <i>JAMA Psychiatry</i> , 2017, 74, 319.	6.0	454
8	Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2015, 206, 93-100.	1.7	315
9	How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. <i>Psychological Medicine</i> , 2003, 33, 1149-1160.	2.7	292
10	Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. <i>Journal of Affective Disorders</i> , 2015, 180, 179-184.	2.0	267
11	Imputing response rates from means and standard deviations in meta-analyses. <i>International Clinical Psychopharmacology</i> , 2005, 20, 49-52.	0.9	261
12	Evidence-Based Guidelines for Mental, Neurological, and Substance Use Disorders in Low- and Middle-Income Countries: Summary of WHO Recommendations. <i>PLoS Medicine</i> , 2011, 8, e1001122.	3.9	246
13	Common mental disorders in asylum seekers and refugees: umbrella review of prevalence and intervention studies. <i>International Journal of Mental Health Systems</i> , 2017, 11, 51.	1.1	238
14	Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. <i>Cmaj</i> , 2009, 180, 291-297.	0.9	229
15	Amitriptyline, the rest: still the leading antidepressant after 40 years of randomised controlled trials. <i>British Journal of Psychiatry</i> , 2001, 178, 129-144.	1.7	188
16	Psychosocial interventions for post-traumatic stress disorder in refugees and asylum seekers resettled in high-income countries: Systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0171030.	1.1	185
17	Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2011, 198, 11-16.	1.7	182
18	WHO Mental Health Gap Action Programme (mhGAP) Intervention Guide: a systematic review of evidence from low and middle-income countries. <i>Evidence-Based Mental Health</i> , 2018, 21, 30-34.	2.2	176

#	ARTICLE	IF	CITATIONS
19	Efficacy of psychosocial interventions for mental health outcomes in low-income and middle-income countries: an umbrella review. <i>Lancet Psychiatry</i> , 2020, 7, 162-172.	3.7	163
20	Clinical interventions for treatment non-adherence in psychosis: Meta-analysis. <i>British Journal of Psychiatry</i> , 2003, 183, 197-206.	1.7	155
21	Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: Systematic review and component network meta-analysis. <i>PLoS Medicine</i> , 2020, 17, e1003262.	3.9	154
22	Side-Effect Profile of Fluoxetine in Comparison with Other SSRIs, Tricyclic and Newer Antidepressants: A Meta-Analysis of Clinical Trial Data. <i>Pharmacopsychiatry</i> , 2005, 38, 69-77.	1.7	148
23	Does the Addition of a Second Antipsychotic Drug Improve Clozapine Treatment?. <i>Schizophrenia Bulletin</i> , 2009, 35, 458-468.	2.3	147
24	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. <i>Frontiers in Pharmacology</i> , 2020, 11, 1205.	1.6	143
25	Efficacy and acceptability of psychosocial interventions in asylum seekers and refugees: systematic review and meta-analysis. <i>Epidemiology and Psychiatric Sciences</i> , 2019, 28, 376-388.	1.8	141
26	Sertraline versus other antidepressive agents for depression. <i>The Cochrane Library</i> , 2010, , CD006117.	1.5	139
27	Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. <i>BMJ: British Medical Journal</i> , 2002, 325, 991-991.	2.4	134
28	Focused psychosocial interventions for children in low-resource humanitarian settings: a systematic review and individual participant data meta-analysis. <i>The Lancet Global Health</i> , 2018, 6, e390-e400.	2.9	119
29	Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis. <i>World Psychiatry</i> , 2018, 17, 316-329.	4.8	119
30	Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2021, 8, 969-980.	3.7	114
31	Psychological therapies for the treatment of mental disorders in low- and middle-income countries affected by humanitarian crises. <i>The Cochrane Library</i> , 2018, 2018, CD011849.	1.5	113
32	Drug-Induced Depression: A Systematic Review to Inform Clinical Practice. <i>Psychotherapy and Psychosomatics</i> , 2004, 73, 207-215.	4.0	111
33	Fluoxetine versus other types of pharmacotherapy for depression. , 2005, , CD004185.		110
34	Pharmacological prevention of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2015, 2, 413-421.	3.7	109
35	Challenges in Developing Evidence-Based Recommendations Using the GRADE Approach: The Case of Mental, Neurological, and Substance Use Disorders. <i>PLoS Medicine</i> , 2010, 7, e1000322.	3.9	105
36	Escitalopram versus other antidepressive agents for depression. <i>The Cochrane Library</i> , 2009, , CD006532.	1.5	102

#	ARTICLE	IF	CITATIONS
37	Mirtazapine versus other antidepressive agents for depression. The Cochrane Library, 2011, , CD006528.	1.5	101
38	Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates. Social Psychiatry and Psychiatric Epidemiology, 1999, 34, 152-156.	1.6	100
39	Non-Specialist Psychosocial Interventions for Children and Adolescents with Intellectual Disability or Lower-Functioning Autism Spectrum Disorders: A Systematic Review. PLoS Medicine, 2013, 10, e1001572.	3.9	99
40	Fluoxetine versus other types of pharmacotherapy for depression. The Cochrane Library, 2013, , CD004185.	1.5	97
41	Management of Acute Stress, PTSD, and Bereavement. JAMA - Journal of the American Medical Association, 2013, 310, 477.	3.8	94
42	Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. Cmaj, 2007, 178, 296-305.	0.9	93
43	Psychotherapies for depression in low- and middle-income countries: a meta-analysis. World Psychiatry, 2018, 17, 90-101.	4.8	92
44	Determinants of subjective quality of life in patients attending community-based mental health services. The South-Verona Outcome Project 5. Acta Psychiatrica Scandinavica, 2002, 105, 131-140.	2.2	90
45	Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. British Journal of Psychiatry, 2013, 203, 179-187.	1.7	84
46	Psychological and Psychosomatic Symptoms of Second Victims of Adverse Events: a Systematic Review and Meta-Analysis. Journal of Patient Safety, 2020, 16, e61-e74.	0.7	80
47	Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic dosages?. International Clinical Psychopharmacology, 2008, 23, 287-290.	0.9	74
48	Safety Reporting and Adverse-Event Profile of Mirtazapine Described in Randomized Controlled Trials in Comparison with Other Classes of Antidepressants in the Acute-Phase Treatment of Adults with Depression. CNS Drugs, 2010, 24, 35-53.	2.7	74
49	Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. International Clinical Psychopharmacology, 2006, 21, 355-362.	0.9	73
50	Efficacy of interventions to reduce coercive treatment in mental health services: umbrella review of randomised evidence. British Journal of Psychiatry, 2021, 218, 185-195.	1.7	73
51	Are we going to increase the use of antidepressants up to that of benzodiazepines?. European Journal of Clinical Pharmacology, 2004, 60, 629-634.	0.8	72
52	Duloxetine versus other anti-depressive agents for depression. The Cochrane Library, 2012, 10, CD006533.	1.5	72
53	Antidepressant Drug Consumption and Public Health Indicators in Italy, 1955 to 2000. Journal of Clinical Psychiatry, 2005, 66, 750-755.	1.1	72
54	Monitoring community psychiatric services in Italy: differences between patients who leave care and those who stay in treatment. British Journal of Psychiatry, 2002, 180, 254-259.	1.7	71

#	ARTICLE	IF	CITATIONS
55	Sertraline versus other antidepressive agents for depression. , 2009, , CD006117.		70
56	Antipsychotic Drug Exposure and Risk of Venous Thromboembolism: A Systematic Review and Meta-Analysis of Observational Studies. Drug Safety, 2014, 37, 79-90.	1.4	70
57	Antidepressants for the treatment of depression in people with cancer. The Cochrane Library, 2015, , CD011006.	1.5	70
58	Investigation of corpus callosum in schizophrenia with diffusion imaging. Schizophrenia Research, 2005, 79, 201-210.	1.1	68
59	Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. International Clinical Psychopharmacology, 2006, 21, 345-353.	0.9	67
60	Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophrenia Research, 2017, 183, 10-21.	1.1	66
61	Antidepressants for the treatment of depression in people with cancer. The Cochrane Library, 2018, 2018, CD011006.	1.5	66
62	Mortality and cause of death among psychiatric patients: a 20-year case-register study in an area with a community-based system of care. Psychological Medicine, 2009, 39, 1875-1884.	2.7	65
63	The evidenceâ€“practice gap in specialist mental healthcare: Systematic review and meta-analysis of guideline implementation studies. British Journal of Psychiatry, 2017, 210, 24-30.	1.7	65
64	Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. Psychotherapy and Psychosomatics, 2021, 90, 41-48.	4.0	63
65	Sex Differences in the Subjective Tolerability of Antipsychotic Drugs. Journal of Clinical Psychopharmacology, 2005, 25, 521-526.	0.7	61
66	Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. International Clinical Psychopharmacology, 2005, 20, 305-309.	0.9	61
67	Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003â€“2004. Pharmacoepidemiology and Drug Safety, 2007, 16, 552-559.	0.9	59
68	Antipsychotic use and risk of lifeâ€“threatening medical events: umbrella review of observational studies. Acta Psychiatrica Scandinavica, 2019, 140, 227-243.	2.2	59
69	Effectiveness of Self-Help Plus in Preventing Mental Disorders in Refugees and Asylum Seekers in Western Europe: A Multinational Randomized Controlled Trial. Psychotherapy and Psychosomatics, 2021, 90, 403-414.	4.0	57
70	Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). , 2000, , CD002791.		56
71	World Health Organization Guidelines for Management of Acute Stress, PTSD, and Bereavement: Key Challenges on the Road Ahead. PLoS Medicine, 2014, 11, e1001769.	3.9	56
72	A systematic review of cognitive effects of exercise in depression. Acta Psychiatrica Scandinavica, 2017, 135, 285-295.	2.2	56

#	ARTICLE	IF	CITATIONS
73	Violence in psychiatric units. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2006, 41, 698-703.	1.6	55
74	Choice of data extraction tools for systematic reviews depends on resources and review complexity. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 506-510.	2.4	55
75	Are All Antidepressants Really the Same? The Case of Fluoxetine. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 850-864.	1.1	55
76	"Wish Bias" in Antidepressant Drug Trials?. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 126-130.	0.7	54
77	Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis. <i>American Journal of Psychiatry</i> , 2021, 178, 424-436.	4.0	54
78	Citalopram versus other anti-depressive agents for depression. <i>The Cochrane Library</i> , 2012, , CD006534.	1.5	53
79	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. <i>BMC Medicine</i> , 2020, 18, 215.	2.3	52
80	Effectiveness of a WHO self-help psychological intervention for preventing mental disorders among Syrian refugees in Turkey: a randomized controlled trial. <i>World Psychiatry</i> , 2022, 21, 88-95.	4.8	52
81	Antidepressant drug prescribing among elderly subjects: a population-based study. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 113-118.	1.3	50
82	Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. , 2009, , CD006324.		50
83	Antipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT Interval. <i>PLoS ONE</i> , 2016, 11, e0148212.	1.1	50
84	Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 812-820.	0.9	49
85	Cortical white-matter microstructure in schizophrenia. <i>British Journal of Psychiatry</i> , 2007, 191, 113-119.	1.7	47
86	Antidepressant drug use in Lombardy, Italy: a population-based study. <i>Journal of Affective Disorders</i> , 2004, 83, 169-175.	2.0	46
87	Assessment of Medication Adherence in Patients With Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2008, 196, 274-281.	0.5	46
88	Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study. <i>Epidemiology and Psychiatric Sciences</i> , 2016, 25, 532-540.	1.8	46
89	Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe. <i>PLoS ONE</i> , 2013, 8, e81208.	1.1	45
90	Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice. <i>Acta Psychiatrica Scandinavica</i> , 2004, 109, 275-278.	2.2	44

#	ARTICLE	IF	CITATIONS
91	Second-Generation Antipsychotics and Risk of Cerebrovascular Accidents in the Elderly. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 468-470.	0.7	44
92	Implementation of Treatment Guidelines for Specialist Mental Health Care. <i>Schizophrenia Bulletin</i> , 2014, 40, 737-739.	2.3	44
93	Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy. <i>PLoS ONE</i> , 2018, 13, e0201371.	1.1	44
94	Mental health services for infectious disease outbreaks including COVID-19: a rapid systematic review. <i>Psychological Medicine</i> , 2020, 50, 2498-2513.	2.7	44
95	Oral and long-acting antipsychotics for relapse prevention in schizophrenia spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. <i>World Psychiatry</i> , 2022, 21, 295-307.	4.8	44
96	Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 251-264.	1.2	43
97	A Systematic Review of the Use of Telepsychiatry in Depression. <i>Community Mental Health Journal</i> , 2021, 57, 93-100.	1.1	43
98	Amitriptyline for Inpatients and SSRIs for Outpatients with Depression? Systematic Review and Meta-Regression Analysis. <i>Pharmacopsychiatry</i> , 2004, 37, 93-97.	1.7	42
99	Reducing the Risk of Cognitive Decline and Dementia: WHO Recommendations. <i>Frontiers in Neurology</i> , 2021, 12, 765584.	1.1	42
100	Forty years without mental hospitals in Italy. <i>International Journal of Mental Health Systems</i> , 2018, 12, 43.	1.1	41
101	Closing forensic psychiatric hospitals in Italy: a new revolution begins?. <i>British Journal of Psychiatry</i> , 2015, 206, 445-446.	1.7	40
102	An overview of systematic reviews on mental health promotion, prevention, and treatment of common mental disorders for refugees, asylum seekers, and internally displaced persons. <i>The Cochrane Library</i> , 2020, 2020, CD013458.	1.5	40
103	Reducing stigma and discrimination associated with COVID-19: early stage pandemic rapid review and practical recommendations. <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, e15.	1.8	39
104	Avoidable mortality of psychiatric patients in an area with a community-based system of mental health care. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 320-325.	2.2	38
105	Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: A 2-year follow-up multicenter study. <i>Schizophrenia Research</i> , 2014, 152, 344-349.	1.1	38
106	Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2237-2255.	0.9	38
107	Factors associated with antipsychotic dosing in psychiatric inpatients: a prospective study. <i>International Clinical Psychopharmacology</i> , 2007, 22, 221-225.	0.9	37
108	Efficacy of selective serotonin reuptake inhibitors and adverse events: Meta-regression and mediation analysis of placebo-controlled trials. <i>British Journal of Psychiatry</i> , 2016, 208, 114-119.	1.7	37

#	ARTICLE	IF	CITATIONS
109	Psychological and social interventions for the prevention of mental disorders in people living in low- and middle-income countries affected by humanitarian crises. The Cochrane Library, 2020, 2020, CD012417.	1.5	37
110	Seven criteria for improving effectiveness trials in psychiatry. Psychological Medicine, 2006, 36, 711.	2.7	36
111	Benzodiazepine use in the real world of psychiatric practice: low-dose, long-term drug taking and low rates of treatment discontinuation. European Journal of Clinical Pharmacology, 2007, 63, 867-873.	0.8	36
112	Milnacipran versus other antidepressive agents for depression. The Cochrane Library, 2014, 2014, CD006529.	1.5	36
113	Validity of the Impact Factor of Journals as a Measure of Randomized Controlled Trial Quality. Journal of Clinical Psychiatry, 2006, 67, 37-40.	1.1	36
114	Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Medicine, 2014, 12, 98.	2.3	35
115	Amitriptyline versus other types of pharmacotherapy for depression. , 2003, , CD004186.		34
116	Effect of Second-Generation Antipsychotics on Employment and Productivity in Individuals with Schizophrenia. Pharmacoeconomics, 2004, 22, 701-718.	1.7	34
117	Fluvoxamine versus other anti-depressive agents for depression. The Cochrane Library, 2010, , CD006114.	1.5	34
118	Aripiprazole Versus Haloperidol in Combination With Clozapine for Treatment-Resistant Schizophrenia in Routine Clinical Care. Journal of Clinical Psychopharmacology, 2011, 31, 266-273.	0.7	33
119	What are evidence-based treatment recommendations?. Epidemiology and Psychiatric Sciences, 2011, 20, 29-31.	1.8	33
120	Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: Systematic review and meta-analysis. Cancer Treatment Reviews, 2015, 41, 714-724.	3.4	33
121	Vortioxetine for depression in adults. The Cochrane Library, 2017, 2017, CD011520.	1.5	33
122	Prescribing Second-Generation Antipsychotics and the Evolving Standard of Care in Italy. Pharmacopsychiatry, 2002, 35, 239-243.	1.7	32
123	Cerebral atrophy and white matter disruption in chronic schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2007, 257, 3-11.	1.8	32
124	[123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. Schizophrenia Research, 2012, 139, 40-45.	1.1	32
125	Paroxetine versus other anti-depressive agents for depression. The Cochrane Library, 2014, , CD006531.	1.5	30
126	Implementation of treatment guidelines for specialist mental health care. The Cochrane Library, 2016, 12, CD009780.	1.5	29

#	ARTICLE	IF	CITATIONS
127	Risk factors of postpartum depression and depressive symptoms: umbrella review of current evidence from systematic reviews and meta-analyses of observational studies. <i>British Journal of Psychiatry</i> , 2022, 221, 591-602.	1.7	29
128	Antidepressant drug prescribing in Italy, 2000: analysis of a general practice database. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 605-609.	0.8	28
129	Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999-2002. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 412-420.	0.9	28
130	Comparison of Patient and Clinician Perspectives in the Assessment of Antipsychotic Medication Adherence. <i>Psychopathology</i> , 2009, 42, 311-317.	1.1	28
131	State of psychiatry in Italy 35 years after psychiatric reform. A critical appraisal of national and local data. <i>International Review of Psychiatry</i> , 2012, 24, 314-320.	1.4	28
132	Esketamine for treatment resistant depression: a trick of smoke and mirrors?. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e79.	1.8	28
133	Global mental health: how are we doing?. <i>World Psychiatry</i> , 2018, 17, 367-368.	4.8	27
134	Effectiveness and cost-effectiveness of Self-Help Plus (SH+) for preventing mental disorders in refugees and asylum seekers in Europe and Turkey: study protocols for two randomised controlled trials. <i>BMJ Open</i> , 2019, 9, e030259.	0.8	27
135	Dealing With Adverse Events: A Meta-analysis on Second Victims' Coping Strategies. <i>Journal of Patient Safety</i> , 2020, 16, e51-e60.	0.7	27
136	Predicting costs of mental health care: a critical literature review. <i>Psychological Medicine</i> , 2007, 37, 467.	2.7	26
137	Antidepressant Drug Prescription and Risk of Abnormal Bleeding. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 33-38.	0.7	26
138	Aripiprazole Versus Haloperidol in Combination With Clozapine for Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 533-537.	0.7	26
139	Implementation of treatment guidelines for specialist mental health care. , 2014, , CD009780.		26
140	Assessment of cerebral blood volume in schizophrenia: A magnetic resonance imaging study. <i>Journal of Psychiatric Research</i> , 2007, 41, 502-510.	1.5	25
141	Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis. <i>Journal of Psychopharmacology</i> , 2009, 23, 539-550.	2.0	25
142	Efficacy and safety of anti-epileptic drugs in patients with active convulsive seizures when no IV access is available: Systematic review and meta-analysis. <i>Epilepsy Research</i> , 2016, 122, 47-55.	0.8	25
143	Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis. <i>BMJ Open</i> , 2017, 7, e013967.	0.8	25
144	Development and implementation of guidelines for the management of depression: a systematic review. <i>Bulletin of the World Health Organization</i> , 2020, 98, 683-697H.	1.5	25

#	ARTICLE	IF	CITATIONS
145	Antidepressant agents: from tricyclics to serotonin uptake inhibitors. <i>Psychological Medicine</i> , 1998, 28, 1169-1178.	2.7	24
146	Psychotropic drug use in Italy, 1984-99: the impact of a change in reimbursement status. <i>International Clinical Psychopharmacology</i> , 2001, 16, 227-233.	0.9	24
147	Efficacy and Tolerability of Milnacipran in the Treatment of Major Depression in Comparison with??Other Antidepressants. <i>CNS Drugs</i> , 2008, 22, 587-602.	2.7	24
148	Generic olanzapine: health authority opportunity or nightmare?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2008, 8, 549-555.	0.7	24
149	EMA must improve the quality of its clinical trial reports. <i>BMJ: British Medical Journal</i> , 2011, 342, d2291-d2291.	2.4	24
150	Changes in the Utilization of Venlafaxine after the Introduction of Generics in Sweden. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 383-393.	1.0	24
151	Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: results and lessons of an underpowered randomised clinical trial. <i>BMC Research Notes</i> , 2014, 7, 731.	0.6	24
152	First-generation antipsychotics and QTc: any role for mediating variables?. <i>Human Psychopharmacology</i> , 2016, 31, 313-318.	0.7	24
153	Sharing all types of clinical data and harmonizing journal standards. <i>BMC Medicine</i> , 2016, 14, 63.	2.3	24
154	A network meta-analysis of psychosocial interventions for refugees and asylum seekers with PTSD. <i>BMJ Global Health</i> , 2021, 6, e005029.	2.0	24
155	Forty years of antidepressant drug trials. <i>Acta Psychiatrica Scandinavica</i> , 2001, 104, 92-95.	2.2	23
156	Update of suicide trends in Italy from 1986 to 1996. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2002, 37, 267-270.	1.6	23
157	A simple approach to manage dosages in drug-epidemiology research. <i>Epidemiologia E Psichiatria Sociale</i> , 2008, 17, 186-187.	1.0	23
158	Antipsychotic drug exposure and risk of pulmonary embolism: a population-based, nested caseâ€“control study. <i>BMC Psychiatry</i> , 2015, 15, 92.	1.1	23
159	Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis. <i>BMC Psychiatry</i> , 2018, 18, 380.	1.1	23
160	Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 697-709.	1.0	23
161	Prevention and management of physical health conditions in adults with severe mental disorders: WHO recommendations. <i>International Journal of Mental Health Systems</i> , 2021, 15, 22.	1.1	23
162	Fluoxetine dose and outcome in antidepressant drug trials. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 379-386.	0.8	22

#	ARTICLE	IF	CITATIONS
163	Varying and "atypical" indications for atypical antipsychotics. <i>Psychopharmacology</i> , 2003, 169, 205-206.	1.5	22
164	Influence of Patient Co-Payments on Atypical Antipsychotic Choice in Poland. <i>Applied Health Economics and Health Policy</i> , 2011, 9, 101-110.	1.0	22
165	Guideline implementation strategies for specialist mental healthcare. <i>Current Opinion in Psychiatry</i> , 2013, 26, 369-375.	3.1	22
166	Antipsychotic drug exposure and risk of fracture. <i>International Clinical Psychopharmacology</i> , 2018, 33, 181-196.	0.9	22
167	Effectiveness of self-help plus (SH+) in reducing anxiety and post-traumatic symptomatology among care home workers during the COVID-19 pandemic: a randomized controlled trial. <i>Royal Society Open Science</i> , 2021, 8, 210219.	1.1	22
168	Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. <i>Trials</i> , 2009, 10, 31.	0.7	21
169	Cluster randomised trials. <i>Epidemiology and Psychiatric Sciences</i> , 2011, 20, 307-309.	1.8	21
170	Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532094270.	1.2	21
171	Meta-analysis of virtual reality exposure therapy for social anxiety disorder. <i>Psychological Medicine</i> , 2023, 53, 2176-2178.	2.7	21
172	Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials. <i>European Psychiatry</i> , 1996, 11, 306-313.	0.1	20
173	A cross-sectional audit of benzodiazepine use among general practice patients. <i>Acta Psychiatrica Scandinavica</i> , 1998, 97, 153-156.	2.2	20
174	Cross-sectional Database Analysis of Antidepressant Prescribing in Italy. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 31-34.	0.7	20
175	Frequency and Adequacy of Depression Treatment in a Canadian Population Sample. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 780-789.	0.9	20
176	Patterns of benzodiazepine use in a Canadian population sample. <i>Epidemiologia E Psichiatria Sociale</i> , 2009, 18, 248-254.	1.0	20
177	Persistence with pharmacological treatment in the specialist mental healthcare of patients with severe mental disorders. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1647-1655.	0.8	20
178	Discussion of the updated WHO recommendations for mental, neurological, and substance use disorders. <i>Lancet Psychiatry</i> , 2016, 3, 1008-1012.	3.7	20
179	Comparative efficacy and acceptability of psychotherapies for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. <i>British Journal of Psychiatry</i> , 2022, 221, 507-519.	1.7	20
180	Does placebo help establish equivalence in trials of new antidepressants?. <i>European Psychiatry</i> , 2000, 15, 268-273.	0.1	19

#	ARTICLE	IF	CITATIONS
181	Direct Costs of Schizophrenia and Related Disorders in Italian Community Mental Health Services: A Multicenter, Prospective 1-Year Followup Study. <i>Schizophrenia Bulletin</i> , 2004, 30, 295-302.	2.3	19
182	Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2005, 40, 72-77.	1.6	19
183	Identification and management of depression in primary care settings. A meta-review of evidence. <i>Epidemiology and Psychiatric Sciences</i> , 2006, 15, 276-283.	1.8	19
184	What is a Cochrane review?. <i>Epidemiology and Psychiatric Sciences</i> , 2011, 20, 231-233.	1.8	19
185	Clinical and regulatory implications of active runâ€n phases in longâ€term studies for bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 328-342.	2.2	19
186	Decisions on WHO's essential medicines need more scrutiny. <i>BMJ</i> , The, 2014, 349, g4798-g4798.	3.0	19
187	Interventions for adults with a history of complex traumatic events: the INCiTE mixed-methods systematic review. <i>Health Technology Assessment</i> , 2020, 24, 1-312.	1.3	19
188	Trends in the use of the Italian Mental Health Act, 1979â€“1997. <i>European Psychiatry</i> , 2004, 19, 444-445.	0.1	18
189	Antipsychotic drug prescribing in the elderly is cause for concern. <i>International Clinical Psychopharmacology</i> , 2004, 19, 347-350.	0.9	18
190	Past use of selective serotonin reuptake inhibitors and the risk of cerebrovascular events in the elderly. <i>International Clinical Psychopharmacology</i> , 2005, 20, 169-171.	0.9	18
191	Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). <i>The Cochrane Library</i> , 2006, , CD002791.	1.5	18
192	Antipsychotic Drugs and Cerebrovascular Events in Elderly Patients with Dementia: A Systematic Review. <i>Mini-Reviews in Medicinal Chemistry</i> , 2008, 8, 776-783.	1.1	18
193	Why it is important to include unpublished data in systematic reviews. <i>Epidemiology and Psychiatric Sciences</i> , 2011, 20, 133-135.	1.8	18
194	What is a multiple treatments meta-analysis?. <i>Epidemiology and Psychiatric Sciences</i> , 2012, 21, 151-153.	1.8	18
195	Prevalence and Correlates of Psychological Distress and Psychiatric Disorders in Asylum Seekers and Refugees Resettled in an Italian Catchment Area. <i>Journal of Immigrant and Minority Health</i> , 2018, 20, 263-270.	0.8	18
196	Beyond pain: can antidepressants improve depressive symptoms and quality of life in patients with neuropathic pain? A systematic review and meta-analysis. <i>Pain</i> , 2019, 160, 2186-2198.	2.0	18
197	Clozapine-treated subjects with treatment-resistant schizophrenia: a systematic review of experimental and observational studies. <i>International Clinical Psychopharmacology</i> , 2002, 17, 189-195.	0.9	17
198	Relationship Between Quality of Reports of Antidepressant Randomized Controlled Trials and Treatment Estimates. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 352-356.	0.7	17

#	ARTICLE	IF	CITATIONS
199	Recent approaches to provision of mental healthcare in refugee populations. <i>Current Opinion in Psychiatry</i> , 2018, 31, 368-372.	3.1	17
200	Ranking antidepressants – Authors' reply. <i>Lancet, The</i> , 2009, 373, 1761-1762.	6.3	16
201	A New Approach to Psychiatric Drug Approval in Europe. <i>PLoS Medicine</i> , 2013, 10, e1001530.	3.9	16
202	Adherence to generic vs. brand antidepressant treatment and the key role of health system factors. <i>Epidemiology and Psychiatric Sciences</i> , 2015, 24, 23-26.	1.8	16
203	Rigour of development of clinical practice guidelines for the pharmacological treatment of bipolar disorder: Systematic review. <i>Journal of Affective Disorders</i> , 2015, 174, 45-50.	2.0	16
204	Cost and Outcome Implications of Using Typical and Atypical Antipsychotics in Ordinary Practice in Italy. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 1293-1299.	1.1	16
205	Epidemiology of First- and Second-generation Antipsychotic Agents in Lombardy, Italy. <i>Pharmacopsychiatry</i> , 2005, 38, 128-131.	1.7	15
206	Validity of indirect comparisons in meta-analysis. <i>Lancet, The</i> , 2007, 369, 270-271.	6.3	15
207	Adverse effects of antipsychotic drugs: survey of doctors' versus patients' perspective. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2012, 47, 157-164.	1.6	15
208	Use of antipsychotic drugs and mood stabilizers in women of childbearing age with schizophrenia and bipolar disorder: epidemiological survey. <i>Epidemiology and Psychiatric Sciences</i> , 2013, 22, 355-361.	1.8	15
209	Implementing a data sharing culture. <i>Epidemiology and Psychiatric Sciences</i> , 2016, 25, 289-290.	1.8	15
210	New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base. <i>Epidemiology and Psychiatric Sciences</i> , 2017, 26, 231-233.	1.8	15
211	Ongoing initiatives within the Scottish National Health Service to affect the prescribing of selective serotonin reuptake inhibitors and their influence. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 535-547.	0.6	15
212	Efficacy and acceptability of antidepressants in patients with ischemic heart disease. <i>International Clinical Psychopharmacology</i> , 2019, 34, 65-75.	0.9	15
213	The Italian mental health-care reform: public health lessons. <i>Bulletin of the World Health Organization</i> , 2018, 96, 731-731A.	1.5	15
214	Economic Evaluation of Antidepressive Agents: A Systematic Critique of Experimental and Observational Studies. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 145-154.	0.7	14
215	Head-To-Head Comparison of the Costs of Atypical Antipsychotics. <i>CNS Drugs</i> , 2005, 19, 935-950.	2.7	14
216	Relationship between Self-Reported and Observer-Reported Ratings for Psychopathology in Psychiatric Inpatients. <i>Psychopathology</i> , 2007, 40, 418-423.	1.1	14

#	ARTICLE	IF	CITATIONS
217	Generic atypical antipsychotic drugs in Belgium: their influence and implications. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 551-561.	0.6	14
218	Benzodiazepines and risk of dementia: true association or reverse causation?. <i>Epidemiology and Psychiatric Sciences</i> , 2013, 22, 307-308.	1.8	14
219	Cochrane for global mental health. <i>Lancet Psychiatry</i> , 2017, 4, e6.	3.7	14
220	Impact of maternal mental health interventions on child-related outcomes in low- and middle-income countries: a systematic review and meta-analysis. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e174.	1.8	14
221	Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic Study. <i>CNS Drugs</i> , 2021, 35, 655-665.	2.7	14
222	Guideline implementation in mental health: Current status and future goals. <i>Epidemiology and Psychiatric Sciences</i> , 2012, 21, 227-229.	1.8	13
223	Dichotomizing rating scale scores in psychiatry: a bad idea?. <i>Epidemiology and Psychiatric Sciences</i> , 2013, 22, 17-19.	1.8	13
224	Potential to Enhance the Prescribing of Generic Drugs in Patients with Mental Health Problems in Austria; Implications for the Future. <i>Frontiers in Pharmacology</i> , 2012, 3, 198.	1.6	13
225	Parent skills training for parents of children or adults with developmental disorders: systematic review and meta-analysis protocol. <i>BMJ Open</i> , 2014, 4, e005799-e005799.	0.8	13
226	Reasons for initiating long-acting antipsychotics in psychiatric practice: findings from the STAR Network Depot Study. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532097810.	1.2	13
227	Health status, resource consumption, and costs of dysthymia. A multi-center two-year longitudinal study. <i>Journal of Affective Disorders</i> , 2006, 90, 181-186.	2.0	12
228	Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. <i>International Journal of Clinical Practice</i> , 2013, 67, 170-180.	0.8	12
229	Discontinuing benzodiazepines: best practices. <i>Epidemiology and Psychiatric Sciences</i> , 2016, 25, 214-216.	1.8	12
230	Mapping actions to improve access to medicines for mental disorders in low and middle income countries. <i>Epidemiology and Psychiatric Sciences</i> , 2017, 26, 481-490.	1.8	12
231	Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophrenia-spectrum disorders: findings from the STAR Network Depot Study. <i>International Clinical Psychopharmacology</i> , 2020, 35, 214-220.	0.9	12
232	The Qualyop Project 1: Monitoring the Dismantlement of Italian Public Psychiatric Hospitals Characteristics of Patients Scheduled for Discharge. <i>International Journal of Social Psychiatry</i> , 1999, 45, 79-92.	1.6	11
233	Worrying Patterns of Out-Patient Psychotropic Drug Prescribing in Children and Adolescents. <i>Psychotherapy and Psychosomatics</i> , 2005, 74, 189-190.	4.0	11
234	What is a risk ratio?. <i>Epidemiologia E Psichiatria Sociale</i> , 2007, 16, 20-21.	1.0	11

#	ARTICLE	IF	CITATIONS
235	Thirtieth birthday of the Italian psychiatric reform: research for identifying its active ingredients is urgently needed. <i>Journal of Epidemiology and Community Health</i> , 2008, 62, 1021-1021.	2.0	11
236	Superiority, equivalence or non-inferiority?. <i>Epidemiology and Psychiatric Sciences</i> , 2009, 18, 311-313.	1.8	11
237	Why internal and external validity of experimental studies are relevant for clinical practice?. <i>Epidemiologia E Psichiatria Sociale</i> , 2009, 18, 101-103.	1.0	11
238	Access to mental health services and psychotropic drug use in refugees and asylum seekers hosted in high-income countries. <i>Epidemiology and Psychiatric Sciences</i> , 2015, 24, 379-381.	1.8	11
239	Using GRADE to update WHO recommendations for MNS. <i>Lancet Psychiatry</i> , the, 2015, 2, 1054-1056.	3.7	11
240	Pragmatic design in randomized controlled trials. <i>Psychological Medicine</i> , 2015, 45, 225-230.	2.7	11
241	Are trials of psychological and psychosocial interventions for schizophrenia and psychosis included in the NICE guidelines pragmatic? A systematic review. <i>PLoS ONE</i> , 2019, 14, e0222891.	1.1	11
242	Behavioural activation therapy for depression in adults with non-communicable diseases. <i>The Cochrane Library</i> , 2020, 2020, CD013461.	1.5	11
243	Association of traumatic events with levels of psychological distress and depressive symptoms in male asylum seekers and refugees resettled in Italy. <i>BMC Psychiatry</i> , 2020, 20, 576.	1.1	11
244	If You Could Only Choose Five Psychotropic Medicines: Updating the Interagency Emergency Health Kit. <i>PLoS Medicine</i> , 2011, 8, e1001030.	3.9	11
245	Colchicine allows prolonged survival of highly reactive renal allograft in the rat.. <i>Journal of the American Society of Nephrology: JASN</i> , 1993, 4, 1294-1299.	3.0	11
246	Polycystic ovary syndrome and postpartum depression: A systematic review and meta-analysis of observational studies. <i>Journal of Affective Disorders</i> , 2022, 299, 463-469.	2.0	11
247	Antidepressant Pharmacoeconomics in a General Population Sample. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 285-587.	0.7	10
248	Drug treatment modalities in psychiatric inpatient practice. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 136-142.	1.8	10
249	Bias in the evaluation of antidepressants. <i>Epidemiologia E Psichiatria Sociale</i> , 2005, 14, 55-57.	1.0	10
250	Explanatory and pragmatic trials. <i>Epidemiologia E Psichiatria Sociale</i> , 2007, 16, 124-125.	1.0	10
251	Antidepressants and suicide symptoms: compelling new insights from the FDA's analysis of individual patient level data. <i>Evidence-Based Mental Health</i> , 2008, 11, 34-35.	2.2	10
252	What is the WHO essential medicines list?. <i>Epidemiology and Psychiatric Sciences</i> , 2012, 21, 343-345.	1.8	10

#	ARTICLE	IF	CITATIONS
253	Schizophrenia trials conducted in African countries: a drop of evidence in the ocean of morbidity?. <i>International Journal of Mental Health Systems</i> , 2012, 6, 9.	1.1	10
254	Making the use of psychotropic drugs more rational through the development of GRADE recommendations in specialist mental healthcare. <i>International Journal of Mental Health Systems</i> , 2013, 7, 14.	1.1	10
255	Celebrating the 40th anniversary of the Italian Mental Health reform. <i>Epidemiology and Psychiatric Sciences</i> , 2018, 27, 311-313.	1.8	10
256	Mediators of focused psychosocial support interventions for children in low-resource humanitarian settings: analysis from an Individual Participant Dataset with 3,143 participants. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2020, 61, 584-593.	3.1	10
257	Gaps and challenges: WHO treatment recommendations for tobacco cessation and management of substance use disorders in people with severe mental illness. <i>BMC Psychiatry</i> , 2020, 20, 237.	1.1	10
258	Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study. <i>Psychiatry Research</i> , 2022, 309, 114405.	1.7	10
259	Clinical trials of new antipsychotics: a critical appraisal. <i>International Clinical Psychopharmacology</i> , 1999, 14, 133-137.	0.9	9
260	Clinical databases of patients receiving antidepressants. <i>Journal of Affective Disorders</i> , 2002, 70, 191-196.	2.0	9
261	Epidemiological impact of antidepressant and antipsychotic drugs on the general population. <i>Current Opinion in Psychiatry</i> , 2006, 19, 405-410.	3.1	9
262	Determinants of first- and second-generation antipsychotic drug use in clinically unstable patients with schizophrenia treated in four European countries. <i>International Clinical Psychopharmacology</i> , 2006, 21, 73-79.	0.9	9
263	Mild depression in general practice: is the automatism of antidepressant prescribing an evidence-based approach?. <i>Acta Psychiatrica Scandinavica</i> , 2006, 113, 449-451.	2.2	9
264	CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation?. <i>Psychopharmacology</i> , 2006, 190, 265-268.	1.5	9
265	Regulatory policies on medicines for psychiatric disorders: is Europe on target?. <i>British Journal of Psychiatry</i> , 2007, 190, 91-93.	1.7	9
266	Assessing risk of bias in randomized controlled trials. <i>Epidemiology and Psychiatric Sciences</i> , 2010, 19, 296-297.	1.8	9
267	What is a factorial trial?. <i>Epidemiology and Psychiatric Sciences</i> , 2013, 22, 213-215.	1.8	9
268	On the need for epidemiology in psychiatric sciences. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e1.	1.8	9
269	Trajectories of psychological symptoms and resilience in conflict-affected children in low- and middle-income countries. <i>Clinical Psychology Review</i> , 2020, 82, 101935.	6.0	9
270	Regulatory Issues in Europe. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 545-548.	0.7	9

#	ARTICLE	IF	CITATIONS
271	Depression in adults: drug and physical treatments. <i>Clinical Evidence</i> , 2011, 2011, .	0.2	9
272	Identification and management of depression in primary care settings. A meta-review of evidence. <i>Epidemiologia E Psichiatria Sociale</i> , 2006, 15, 276-83.	1.0	9
273	Community-based interventions for improving mental health in refugee children and adolescents in high-income countries. <i>The Cochrane Library</i> , 2022, 2022, CD013657.	1.5	9
274	Psychotropic drug epidemiology: The road travelled, the road ahead. <i>International Review of Psychiatry</i> , 2005, 17, 143-151.	1.4	8
275	Antidepressant and antipsychotic drug prescribing in Lombardy. <i>Epidemiologia E Psichiatria Sociale</i> , 2006, 15, 59-70.	1.0	8
276	What is a clinical trial protocol?. <i>Epidemiologia E Psichiatria Sociale</i> , 2010, 19, 116-117.	1.0	8
277	Agomelatine and the brave old world of narrative-based medicine: Table 1. <i>Evidence-Based Mental Health</i> , 2012, 15, 2-3.	2.2	8
278	Randomized Trials Published in Chinese or Western Journals. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 354-361.	0.7	8
279	Regulatory science in Europe: the case of schizophrenia trials. <i>Lancet, The</i> , 2013, 382, 1234-1235.	6.3	8
280	Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications. <i>Journal of Pharmaceutical Health Services Research</i> , 2013, 4, 139-150.	0.3	8
281	Psychosocial interventions for children exposed to traumatic events in low- and middle-income countries: study protocol of an individual patient data meta-analysis. <i>Systematic Reviews</i> , 2014, 3, 34.	2.5	8
282	Access to psychotropic medicines in low-resource settings. <i>Lancet Psychiatry</i> , 2016, 3, 913-915.	3.7	8
283	Reviews and Meta-analyses of Psychotherapy Efficacy for Borderline Personality Disorder—Reply. <i>JAMA Psychiatry</i> , 2017, 74, 854.	6.0	8
284	Psychological interventions for positive symptoms in schizophrenia: protocol for a network meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2018, 8, e019280.	0.8	8
285	Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial. <i>Trials</i> , 2020, 21, 695.	0.7	8
286	Efficacy of physical activity interventions on psychological outcomes in refugee, asylum seeker and migrant populations: A systematic review and meta-analysis. <i>Psychology of Sport and Exercise</i> , 2021, 54, 101901.	1.1	8
287	How does context influence the delivery of mental health interventions for asylum seekers and refugees in low- and middle-income countries? A qualitative systematic review. <i>International Journal of Mental Health Systems</i> , 2021, 15, 80.	1.1	8
288	Early pharmacological interventions for universal prevention of post-traumatic stress disorder (PTSD). <i>The Cochrane Library</i> , 2022, 2022, CD013443.	1.5	8

#	ARTICLE	IF	CITATIONS
289	QUALYOP Project 2: monitoring the dismantling of Italian psychiatric hospitals. Psychotropic drug use in 1072 inpatients. , 1999, 8, 331-337.		7
290	Development of a registry for monitoring psychotropic drug prescriptions: aims, methods and implications for ordinary practice and research. International Journal of Methods in Psychiatric Research, 2005, 14, 151-157.	1.1	7
291	Paroxetine versus other anti-depressive agents for depression. , 2007, , .		7
292	Venlafaxine versus other anti-depressive agents for depression. The Cochrane Library, 2007, , .	1.5	7
293	Intramuscular haloperidol plus promethazine is more effective and safer than haloperidol alone for rapid tranquillisation of agitated mentally ill patients. Evidence-Based Mental Health, 2008, 11, 86-87.	2.2	7
294	Suicide prevention strategies and mental disorders. Epidemiologia E Psichiatria Sociale, 2009, 18, 169-171.	1.0	7
295	Stressful Life Events and Social Health Factors in Women Using Anxiolytics and Antidepressants: An Italian Observational Study in Community Pharmacies. Gender Medicine, 2011, 8, 80-92.	1.4	7
296	Mental disorders and conditions specifically related to stress. Epidemiology and Psychiatric Sciences, 2013, 22, 195-196.	1.8	7
297	Do antidepressants prolong the QT interval?. Epidemiology and Psychiatric Sciences, 2014, 23, 19-20.	1.8	7
298	Can systematic reviews contribute to regulatory decisions?. European Journal of Clinical Pharmacology, 2017, 73, 507-509.	0.8	7
299	Access to and Use of Psychiatric Services by Migrants Resettled in Northern Italy. Journal of Immigrant and Minority Health, 2018, 20, 1309-1316.	0.8	7
300	Prevalence and treatment of neurological and psychiatric disorders among tertiary hospitals in Pakistan; findings and implications. Hospital Practice (1995), 2020, 48, 145-160.	0.5	7
301	Introduction and methods of the evidence-based guidelines for the diagnosis and management of autism spectrum disorder by the Italian National Institute of Health. Health and Quality of Life Outcomes, 2020, 18, 81.	1.0	7
302	Mapping the selection, availability, price and affordability of essential medicines for mental health conditions at a global level. Epidemiology and Psychiatric Sciences, 2022, 31, e22.	1.8	7
303	Drug epidemiology in Italy: methods and ethical issues. The example of psychiatry. Pharmacoepidemiology and Drug Safety, 2001, 10, 647.	0.9	6
304	Patient Opinions on the Benefits of Treatment Programs in Residential Psychiatric Care. Canadian Journal of Psychiatry, 2004, 49, 613-620.	0.9	6
305	International Dosage Differences in Fluoxetine Clinical Trials. Canadian Journal of Psychiatry, 2005, 50, 31-38.	0.9	6
306	The Prevalence of Antidepressant and Antipsychotic Drug Prescribing in Lombardy, Italy. Journal of Clinical Psychopharmacology, 2005, 25, 92-94.	0.7	6

#	ARTICLE	IF	CITATIONS
307	What is a systematic review?. <i>Epidemiologia E Psichiatria Sociale</i> , 2006, 15, 174-175.	1.0	6
308	Evidence-based psychopharmacology: an agenda for the future. <i>Evidence-Based Mental Health</i> , 2007, 10, 4-6.	2.2	6
309	Understanding antipsychotic non-classical prescriptions: a quantitative and qualitative approach. <i>Epidemiologia E Psichiatria Sociale</i> , 2008, 17, 236-241.	1.0	6
310	What is the European Medicines Agency?. <i>Epidemiology and Psychiatric Sciences</i> , 2012, 21, 245-247.	1.8	6
311	Drug dose as mediator of treatment effect in antidepressant drug trials: the case of fluoxetine. <i>Acta Psychiatrica Scandinavica</i> , 2015, 131, 408-416.	2.2	6
312	Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study. <i>Epidemiology and Psychiatric Sciences</i> , 2016, 25, 21-23.	1.8	6
313	Improving access to medicines for mental disorders in low-resource settings: some achievements but still a long road ahead. <i>Epidemiology and Psychiatric Sciences</i> , 2016, 25, 1-3.	1.8	6
314	Global mental health: good news, bad news and responsibilities for the future. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e76.	1.8	6
315	Safety of Psychotropic Medications in People With COVID-19: Evidence Review and Practical Recommendations. <i>Focus (American Psychiatric Publishing)</i> , 2020, 18, 466-481.	0.4	6
316	Does mental health staffing level affect antipsychotic prescribing? Analysis of Italian national statistics. <i>PLoS ONE</i> , 2018, 13, e0193216.	1.1	6
317	Development of a core outcome set for multimorbidity trials in low/middle-income countries (COSMOS): study protocol. <i>BMJ Open</i> , 2022, 12, e051810.	0.8	6
318	Scientists Against War: A Plea to World Leaders for Better Governance. <i>Sleep and Vigilance</i> , 2022, 6, 1-6.	0.4	6
319	Factors Associated with Medication Adherence to Long-Acting Injectable Antipsychotics: Results from the STAR Network Depot Study. <i>Pharmacopsychiatry</i> , 2022, 55, 281-289.	1.7	6
320	Cost-effectiveness of the Self-Help Plus Intervention for Adult Syrian Refugees Hosted in Turkey. <i>JAMA Network Open</i> , 2022, 5, e2211489.	2.8	6
321	Routine outcome monitoring in clinical practice: service and non-service costs of psychiatric patients attending a Community Mental Health Centre in Italy. <i>European Psychiatry</i> , 2004, 19, 469-477.	0.1	5
322	Generating psychotropic drug exposure data from computer-based medical records. <i>Computer Methods and Programs in Biomedicine</i> , 2006, 83, 120-124.	2.6	5
323	Making the best use of available evidence: the case of new generation antidepressants: A response to: Are all antidepressants equal?. <i>Evidence-Based Mental Health</i> , 2009, 12, 101-104.	2.2	5
324	SSRI plus supportive care more effective than supportive care alone for mild to moderate depression. <i>Evidence-Based Mental Health</i> , 2009, 12, 109-109.	2.2	5

#	ARTICLE	IF	CITATIONS
325	Reboxetine versus other antidepressive agents for depression. The Cochrane Library, 2009, , .	1.5	5
326	Cochrane reviews impact on mental health policy and practice. <i>Epidemiology and Psychiatric Sciences</i> , 2011, 20, 211-214.	1.8	5
327	Antidepressant dose and the risk of deliberate self-harm. <i>Epidemiology and Psychiatric Sciences</i> , 2014, 23, 329-331.	1.8	5
328	Access and use of psychotropic medicines in low-resource settings. <i>Epidemiology and Psychiatric Sciences</i> , 2015, 24, 206-209.	1.8	5
329	Real-world data on new users of atypical antipsychotics: characterisation, prescription patterns, healthcare costs and early cardio-metabolic occurrences from a large Italian database. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1301-1310.	0.8	5
330	Esketamine clinical trials: reply to Maju et al.. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e122.	1.8	5
331	Self-help plus for refugees and asylum seekers; study protocol for a series of individual participant data meta-analyses. <i>HÅrre Utbildning</i> , 2021, 12, 1930690.	1.4	5
332	The BPRS-E as Predictor of Length of Stay in a Residential Facility. <i>Psychiatric Services</i> , 2005, 56, 755-756.	1.1	5
333	Aripiprazole in Addition to Clozapine in Partially Responsive Patients with Schizophrenia: A Critical Review of Case Series. <i>Clinical Schizophrenia and Related Psychoses</i> , 2008, 1, 341-347.	1.4	5
334	Preventing the mental health consequences of war in refugee populations. <i>Epidemiology and Psychiatric Sciences</i> , 2022, 31, e24.	1.8	5
335	Costi diretti della schizofrenia nei dipartimenti di salute mentale italiani. <i>Pharmacoeconomics Italian Research Articles</i> , 2002, 4, 81-89.	0.2	4
336	Evidenceâ€‘based medicine and medicineâ€‘based evidence. <i>Neurological Sciences</i> , 2005, 26, 145-146.	0.9	4
337	New generation psychotropics and the automatism of prescribing. <i>International Review of Psychiatry</i> , 2005, 17, 139-141.	1.4	4
338	What is an individual patient data meta-analysis?. <i>Epidemiologia E Psichiatria Sociale</i> , 2007, 16, 203-204.	1.0	4
339	Using the needs of WHO to prioritise Cochrane reviews: The case of antipsychotic drugs. <i>International Journal of Mental Health Systems</i> , 2011, 5, 25.	1.1	4
340	Do Cochrane systematic reviews meet WHO needs?. <i>Addiction</i> , 2015, 110, 899-900.	1.7	4
341	Antipsychotic drug exposure and risk of myocardial infarction. <i>Epidemiology and Psychiatric Sciences</i> , 2017, 26, 18-21.	1.8	4
342	Parkinsonian axial signs in schizophrenia. <i>Parkinsonism and Related Disorders</i> , 2017, 36, 89-92.	1.1	4

#	ARTICLE	IF	CITATIONS
343	Trends in the prescribing of antipsychotic medicines in Pakistan: implications for the future. <i>Current Medical Research and Opinion</i> , 2019, 35, 51-61.	0.9	4
344	Poor implementation of the EU clinical trial regulation is a major threat for pragmatic trials in European countries. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e126.	1.8	4
345	Regulatory requirements for psychological interventions. <i>Lancet Psychiatry</i> , 2021, 8, 174-176.	3.7	4
346	Primary-level and community worker interventions for the prevention of mental disorders and the promotion of well-being in low- and middle-income countries. <i>The Cochrane Library</i> , 0, , .	1.5	4
347	Expanding access to long-acting antipsychotics in low-income and middle-income countries. <i>Lancet Psychiatry</i> , 2021, 8, 1034-1035.	3.7	4
348	The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 784366.	1.3	4
349	Why internal and external validity of experimental studies are relevant for clinical practice?. <i>Epidemiologia E Psichiatria Sociale</i> , 2009, 18, 101-3.	1.0	4
350	Preventing relapse in schizophrenia needs better evidence. <i>Lancet</i> , 2022, 399, 773-775.	6.3	4
351	Health status, resource consumption, and costs of dysthymic patients in Italian primary care. <i>Epidemiologia E Psichiatria Sociale</i> , 2004, 13, 120-125.	1.0	3
352	Allocation concealment and blinding in clinical trials. <i>Epidemiologia E Psichiatria Sociale</i> , 2008, 17, 115-116.	1.0	3
353	Outcome reporting bias in clinical trials. <i>Epidemiologia E Psichiatria Sociale</i> , 2009, 18, 17-18.	1.0	3
354	Geneva calling: WHO resolution on mental disorders. <i>International Journal of Mental Health Systems</i> , 2012, 6, 6.	1.1	3
355	Treatment Choices in Women with Bipolar Disorder Seeking Pregnancy: A Clinical Case Illustration. <i>Case Reports in Psychiatry</i> , 2013, 2013, 1-3.	0.2	3
356	Autism spectrum disorders: weighing the risk of SSRI exposure in pregnancy. <i>Epidemiology and Psychiatric Sciences</i> , 2014, 23, 231-233.	1.8	3
357	Attention-deficit/hyperactivity disorder (ADHD): from randomised controlled trials to evidence-based clinical services. <i>Epidemiology and Psychiatric Sciences</i> , 2017, 26, 445-447.	1.8	3
358	Regulatory meta-analyses for the evaluation of psychotropic medicines. <i>Lancet Psychiatry</i> , 2017, 4, 660-661.	3.7	3
359	Evidence, knowledge, implementation: glossary of terminology. <i>Epidemiology and Psychiatric Sciences</i> , 2017, 26, 103-104.	1.8	3
360	Mapping the evidence on pharmacological interventions for non-affective psychosis in humanitarian non-specialised settings: a UNHCR clinical guidance. <i>BMC Medicine</i> , 2017, 15, 197.	2.3	3

#	ARTICLE	IF	CITATIONS
361	An overview of systematic reviews on mental health promotion, prevention, and treatment of common mental disorders for refugees, asylum seekers, and internally displaced persons. The Cochrane Library, 0, , .	1.5	3
362	Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence. <i>BMJ Open</i> , 2020, 10, e035073.	0.8	3
363	Evidence-based interventions for global mental health: role and mission of a new Cochrane initiative. , 2017, 4, ED000120.		3
364	Which psychotherapy is effective in panic disorder? And which delivery formats are supported by the evidence? Study protocol for two systematic reviews and network meta-analyses. <i>BMJ Open</i> , 2020, 10, e038909.	0.8	3
365	Depression in adults: drug and physical treatments. <i>Clinical Evidence</i> , 2007, 2007, .	0.2	3
366	Studies of privileged sites and organ transplantation. <i>Experimental Nephrology</i> , 1993, 1, 120-7.	0.4	3
367	Suicide prevention strategies and mental disorders. <i>Epidemiologia E Psichiatria Sociale</i> , 2009, 18, 169-71.	1.0	3
368	Assessing risk of bias in randomized controlled trials. <i>Epidemiologia E Psichiatria Sociale</i> , 2010, 19, 296-7.	1.0	3
369	Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries. <i>Epidemiology and Psychiatric Sciences</i> , 2022, 31, e34.	1.8	3
370	The Changing Pattern of Inpatient Antipsychotic Drug Use in Italy. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 559-561.	0.7	2
371	What is a forest plot?. <i>Epidemiology and Psychiatric Sciences</i> , 2006, 15, 258-259.	1.8	2
372	What is an intention to treat analysis?. <i>Epidemiologia E Psichiatria Sociale</i> , 2008, 17, 26-27.	1.0	2
373	Review: maintenance antidepressants reduce risk of relapse but effect is not as great in recurrent depression. <i>Evidence-Based Mental Health</i> , 2009, 12, 79-79.	2.2	2
374	Comparative efficacy of anti-manic drugs in acute mania – Authors' reply. <i>Lancet</i> , The, 2012, 379, 894.	6.3	2
375	Bupropion versus other antidepressive agents for depression. The Cochrane Library, 0, , .	1.5	2
376	Clinical use of the diagnostic criteria for major depressive disorder. <i>Epidemiology and Psychiatric Sciences</i> , 2015, 24, 464-465.	1.8	2
377	Authors' reply. <i>British Journal of Psychiatry</i> , 2015, 207, 177-177.	1.7	2
378	Global mental health: achievements, concerns and (unanswered) questions. <i>Epidemiology and Psychiatric Sciences</i> , 2016, 25, 493-494.	1.8	2

#	ARTICLE	IF	CITATIONS
379	Stopping antidepressants following depression. <i>BMJ, The</i> , 2016, 352, i220.	3.0	2
380	Public health psychopharmacology: a new research discipline comes of age?. <i>Epidemiology and Psychiatric Sciences</i> , 2018, 27, 24-28.	1.8	2
381	Medicine-based evidence: the case of antidepressants in patients with coronary artery disease. <i>Epidemiology and Psychiatric Sciences</i> , 2019, 28, 18-20.	1.8	2
382	Letters to the Editor. <i>American Journal of Psychiatry</i> , 1998, 155, 152a-153.	4.0	2
383	Discharges of patients from public psychiatric hospitals in Italy between 1994 and 2000. <i>International Journal of Social Psychiatry</i> , 2003, 49, 27-34.	1.6	2
384	Long-term effectiveness of Self-Help Plus in refugees and asylum seekers resettled in Western Europe: 12-month outcomes of a randomised controlled trial. <i>Epidemiology and Psychiatric Sciences</i> , 2022, 31, .	1.8	2
385	Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: An effect size analysis. <i>European Psychiatry</i> , 1996, 11, 412-415.	0.1	1
386	Evaluation of dehospitalization policies of the former psychiatric hospitals of Regione Lombardia. QUALYOP study results. I: Structural resources, organizational procedures and activities. <i>Epidemiologia E Psichiatria Sociale</i> , 1996, 5, 59-71.	1.0	1
387	Effect of Antipsychotic Drugs on Cerebrovascular Morbidity and Mortality: A Systematic Review. <i>Current Drug Therapy</i> , 2006, 1, 241-248.	0.2	1
388	Decision models in the evaluation of psychotropic drugs. <i>European Journal of Health Economics</i> , 2006, 7, 218-220.	1.4	1
389	Review: antidepressant plus antipsychotic increases clinical response rates in psychotic depression. <i>Evidence-Based Mental Health</i> , 2007, 10, 10-10.	2.2	1
390	Adding aripiprazole improves major depressive disorder following incomplete response to antidepressants alone. <i>Evidence-Based Mental Health</i> , 2008, 11, 15-15.	2.2	1
391	The attitude of patients with mental disorders towards pharmacological and non-pharmacological treatments: emerging implications for clinical practice, service organization and research. <i>Epidemiologia E Psichiatria Sociale</i> , 2008, 17, 171-173.	1.0	1
392	Review: Is aripiprazole as effective as risperidone in people with schizophrenia?. <i>Evidence-Based Mental Health</i> , 2010, 13, 51-51.	2.2	1
393	Authors' reply to Magrini and colleagues. <i>BMJ, The</i> , 2014, 349, g5705-g5705.	3.0	1
394	Beneficial and harmful consequences of prepartum and postpartum antidepressant exposure: TableÂ1. <i>Evidence-Based Mental Health</i> , 2014, 17, 69-71.	2.2	1
395	Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple-Treatments Meta-Analysis. <i>Focus (American Psychiatric Publishing)</i> , 2014, 12, 192-204.	0.4	1
396	From the 16th to the 21st Century: how we approach mental health problems and where do we go next?. <i>Epidemiology and Psychiatric Sciences</i> , 2015, 24, 365-367.	1.8	1

#	ARTICLE	IF	CITATIONS
397	Social and environmental adversities, neurobiological processes and mental disorders. <i>Epidemiology and Psychiatric Sciences</i> , 2016, 25, 93-94.	1.8	1
398	Safety of psychotropic medicines: looking beyond randomised evidence. <i>Epidemiology and Psychiatric Sciences</i> , 2018, 27, 529-530.	1.8	1
399	Psychosocial interventions for Post-Traumatic Stress Disorder in refugees and asylum seekers. <i>Rivista Sperimentale Di Freniatria</i> , 2017, , 51-66.	0.1	1
400	Review: antipsychotic plus mood stabiliser co-therapy is more effective than mood stabiliser mono-therapy at reducing acute bipolar mania. <i>Evidence-Based Mental Health</i> , 2007, 10, 83.	2.2	1
401	Psychological and social interventions for the promotion of mental health in people living in low- and middle-income countries affected by humanitarian crises. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	1
402	Reply to the Comments by Doherty et al.. <i>Psychotherapy and Psychosomatics</i> , 2021, 90, 140-141.	4.0	1
403	Italy's mad law. <i>Acta Psychiatrica Scandinavica</i> , 2000, 102, 396-396.	2.2	0
404	Review: multiple daily doses of antidepressants are not more effective than single daily doses. <i>Evidence-Based Mental Health</i> , 2002, 5, 57-57.	2.2	0
405	Collaborative care involving pharmacotherapy was cost effective for increasing anxiety free days in panic disorder. <i>Evidence-Based Medicine</i> , 2003, 8, 126-126.	0.6	0
406	La ricerca farmaco-economica italiana su riviste internazionali. <i>Pharmacoeconomics Italian Research Articles</i> , 2004, 6, 115-120.	0.2	0
407	Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects. <i>Evidence-Based Mental Health</i> , 2007, 10, 74-74.	2.2	0
408	Cognitive improvements with antipsychotics: real or practice effect?. <i>Evidence-Based Mental Health</i> , 2008, 11, 42-42.	2.2	0
409	Getting Through the Quicksand of the Relationship between Drugs and Suicide. <i>Drug Safety</i> , 2011, 34, 397-401.	1.4	0
410	PP063 "Changes in the utilisation of venlafaxine after the introduction of generics in Sweden: Implications for other countries. <i>Clinical Therapeutics</i> , 2013, 35, e37.	1.1	0
411	Review: short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference in French health insurance costs. <i>Evidence-Based Mental Health</i> , 2013, 16, 51-51.	2.2	0
412	Sharing (all) clinical data. <i>European Journal of Internal Medicine</i> , 2016, 33, e27.	1.0	0
413	Role of Co-occurring Alcohol and Substances Abuse on QTc Interval Prolongation Among Psychiatric Patients: A Cross-sectional National Survey. <i>European Psychiatry</i> , 2017, 41, S201-S202.	0.1	0
414	P.220 Early cardio-metabolic occurrences after atypical antipsychotic treatment initiation: Real world evidence from a large Italian claim database. <i>European Neuropsychopharmacology</i> , 2019, 29, S169-S170.	0.3	0

#	ARTICLE	IF	CITATIONS
415	Vortioxetine for depression in adults. <i>BJ Psych Advances</i> , 2019, 25, 2-2.	0.5	0
416	Is the efficacy of antidepressants in panic disorder mediated by adverse events? A mediational analysis. <i>PLoS ONE</i> , 2017, 12, e0178617.	1.1	0
417	PMH26 Real World Evidence Analysis of Atypical Antipsychotics, Cardio-Metabolic Profiles and Related Costs: DATA from the Italian Administrative Database of Fondazione Ricerca E Salute (RES). <i>Value in Health</i> , 2020, 23, S588.	0.1	0
418	When important steps for a reliable meta-analysis are missing: the bevacizumab versus ranibizumab case. <i>International Journal of Ophthalmology</i> , 2015, 8, 204-5.	0.5	0
419	Esketamine for treatment-resistant depression in adults. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	0
420	Academic psychiatry and the pharmaceutical industry: useful partnership or dangerous interaction?. <i>Epidemiologia E Psichiatria Sociale</i> , 2007, 16, 189-91.	1.0	0
421	Outcome reporting bias in clinical trials. <i>Epidemiologia E Psichiatria Sociale</i> , 2009, 18, 17-8.	1.0	0
422	Safety of psychotropic medications in people with COVID-19. <i>European Psychiatry</i> , 2021, 64, S93-S93.	0.1	0
423	Title is missing!. , 2020, 17, e1003262.		0
424	Title is missing!. , 2020, 17, e1003262.		0
425	Title is missing!. , 2020, 17, e1003262.		0
426	Title is missing!. , 2020, 17, e1003262.		0
427	Title is missing!. , 2020, 17, e1003262.		0
428	Title is missing!. , 2019, 14, e0222891.		0
429	Title is missing!. , 2019, 14, e0222891.		0
430	Title is missing!. , 2019, 14, e0222891.		0
431	Title is missing!. , 2019, 14, e0222891.		0